A 42-year-old male patient of Chinese origin who had previously undergone surgery for gastric 18 cancer, subsequently complicated by peritoneal carcinosis, presented to the Verona University 19
Hospital Casualty Department for anorexia, vomiting, asthenia, and weight loss. Physical 20 examination revealed ascites and clinical signs of intestinal subocclusion. Nineteen months 21 earlier he had undergone a subtotal distal gastrectomy and lymphadenectomy for a diffuse-type 22 gastric carcinoma with positivity for Helicobacter pylori (pT3-pN9/34-M0). A central venous 23
catheter had been positioned, after which he had been treated with 2 cycles of an ECF 24 chemotherapy protocol (epirubicin, cisplatin and fluorouracil), followed by combined 25 radiotherapy (45 Gy in 25 sessions) and chemotherapy (4 cycles of 5-fluorouracil and folinic 26 acid). Four months later peritoneal carcinosis was detected, so the patient was treated with a 27 further 8 chemotherapy cycles of oxaliplatin, fluorouracil (5-FU) and folinic acid; the last cycle 28 was administered 2 months prior to presentation to the Casualty Department. grow on cycloheximide-containing media, and was negative at the urease test and positive at the 57 nitrate assimilation test. It fermented glucose and sucrose only. All strains gave excellent 58 identification for Candida magnoliae using ID 32C (profile 4020110211, 99.4% agreement) 59 and the YST card for Vitek 2. One of these strains, C. magnoliae SL040806, was selected for 60 further study. 61
To confirm the biochemical identification, genomic DNA was isolated from fungal colonies 62 grown on Sabourad agar plates, as described (8), and sequence analysis of the 18S ribosomal 63 DNA (a highly conserved region in Candida species) was performed, as described by Suzuki et 64 The phylogenetic relationship of C. magnoliae to other Candida spp was investigated by 68 sequencing the internal transcribed spacer (ITS) region located between the 18S and 26S rRNA 69 genes and subdivided into the ITS1 region, between the 18S and 5.8S rRNA genes, and the ITS2 70 region, between the 5.8S and 26S rRNA genes. This region is more divergent and distinctive 71 than the highly conserved rRNA genes for Candida species (10, 17) and has never been 72 examined in C. magnoliae. Primers and conditions used to amplify the ITS region were as 73 described (17). The ITS sequences of the C. magnoliae SL040806 strain and those of the 74 reference strains obtained from GenBank were aligned using the CLUSTAL W program (1) and 75 a phylogenetic tree was generated (Fig. 2) . Phylogenetic analysis was performed according to 76 To the best of our knowledge, Candida magnoliae has been implicated in just one case of human 96 disease (tenosynovitis in an immunocompetent child) (7). Our report describing a bloodstream 97 infection by C. magnoliae in a terminal oncological patient is the first to indicate the role of this 98 yeast also in candidemia. 99
A C C E P T E D
The incidence of bloodstream infection caused by Candida spp. has increased progressively over 100 the past two decades (6,14), and among the Candida species identified to date, Candida albicans 101 ranks first, though recent studies show a shift towards an increasing prevalence of non-albicans 102 species. This change has been attributed in part to the widespread use of antifungal agents and to 103 the increasing number of immunocompromised hosts; however, it may also reflect the increasing 104 awareness of non-C. albicans Candida species as important opportunistic pathogens (3). It hascalorie sweetener and safe for diabetics (18). It is also used in biotechnology to produce mannitolfrom glucose. 114
A worrying feature of the infection caused by C. magnoliae was the very slow growth of the 115 yeast under the conditions recommended by the CLSI (formerly NCCLS) guidelines for 116 antifungal susceptibility tests. Apparently, the yeast was resistant to fluconazole under the 117 modified conditions used by us and the possibility that this resistance was innate was suggested 118
by the strict phylogenetic relationship we found to C. krusei (Fig. 2) . We do not know whether 119 the resistance detected under these conditions was clinically significant since the patient was first 120 treated with amphotericin to which the yeast was "susceptible" under both conditions. Since the 121 shift to fluconazole therapy occurred after three days of amphotericin use, the drop in fever 122 could have been linked to the activity of the first drug used. 
